Good syndrome

Good syndrome is a rare condition in which a person has both a thymoma, a tumour of the thymus gland, and an acquired immune deficiency affecting antibody production. It typically presents in adults, most often in their fifth or sixth decade. The immune deficiency leads to increased susceptibility to infections, similar in some ways to common variable immunodeficiency.

The exact mechanism linking the thymoma to the immune deficiency is not fully understood, but it is thought to involve abnormal immune regulation arising from the thymic tumour. It is not inherited and occurs sporadically. It is diagnosed when a thymoma is found alongside low antibody levels and recurrent infections.

People with Good syndrome often experience recurrent bacterial infections, particularly of the sinuses and lungs, as well as increased susceptibility to certain viral and opportunistic infections. Some also develop autoimmune complications such as pure red cell aplasia, a form of anaemia. Symptoms of the thymoma itself, such as chest discomfort, may also be present.

Yes, it is a serious condition requiring specialist immunology and often oncology input, because of the combination of recurrent infections and the underlying tumour. With appropriate treatment, including immunoglobulin replacement and management of the thymoma, many people achieve good infection control. Long-term monitoring is needed because of ongoing immune deficiency even after the thymoma is treated.

No, Good syndrome is not an inherited condition; it arises sporadically in association with a thymoma rather than being passed down through families. There is no known genetic predisposition identified to date. It differs in this respect from some other primary immunodeficiencies that do run in families.

Treatment usually involves surgical removal of the thymoma where possible, combined with regular immunoglobulin replacement therapy to address the antibody deficiency and reduce infection risk. Prompt treatment of infections as they occur is also important. Ongoing monitoring by an immunology specialist guides adjustments to treatment over time.

Removing the thymoma does not usually reverse the immune deficiency, which tends to persist and require lifelong immunoglobulin replacement therapy. With good management, though, infection frequency and severity can be substantially reduced. Regular specialist follow-up remains important even after the thymoma has been successfully treated.

Both conditions cause low antibody levels and recurrent infections, but Good syndrome is specifically associated with a thymoma, whereas common variable immunodeficiency (CVID) occurs without this tumour and often has an earlier age of onset. The presence of a thymoma on imaging is the key distinguishing feature. Both are managed with immunoglobulin replacement therapy, though Good syndrome also requires management of the thymoma itself.

Ongoing follow-up typically includes regular immunology review, monitoring of antibody levels and infection frequency, and periodic imaging to check for thymoma recurrence. Any new or recurrent infections should be reported promptly for assessment and treatment. Lifelong specialist follow-up is generally recommended rather than discharge after initial treatment.

See a doctor if you have recurrent infections alongside a known or suspected thymus tumour, or unexplained recurrent infections in adulthood that seem out of proportion to normal illness patterns. A private immunology referral for assessment and antibody testing can typically be arranged within about two weeks. Because the condition is rare, referral to a specialist immunology centre gives the best chance of an accurate diagnosis and tailored treatment plan.